Logo image of VACC

VACCITECH PLC (VACC) Stock Fundamental Analysis

USA - NASDAQ:VACC - US91864C1071 - ADR

5 USD
+0.51 (+11.36%)
Last: 11/6/2023, 8:00:01 PM
4.9 USD
-0.1 (-2%)
After Hours: 11/6/2023, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, VACC scores 3 out of 10 in our fundamental rating. VACC was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VACC as it has an excellent financial health rating, but there are worries on the profitability. VACC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

VACC had negative earnings in the past year.
VACC had a negative operating cash flow in the past year.
VACC Yearly Net Income VS EBIT VS OCF VS FCFVACC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of VACC (-22.32%) is better than 80.10% of its industry peers.
VACC has a better Return On Equity (-25.29%) than 83.25% of its industry peers.
Industry RankSector Rank
ROA -22.32%
ROE -25.29%
ROIC N/A
ROA(3y)-17.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VACC Yearly ROA, ROE, ROICVACC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VACC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VACC Yearly Profit, Operating, Gross MarginsVACC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

VACC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VACC has been increased compared to 1 year ago.
VACC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VACC Yearly Shares OutstandingVACC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
VACC Yearly Total Debt VS Total AssetsVACC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 3.18 indicates that VACC is not in any danger for bankruptcy at the moment.
VACC's Altman-Z score of 3.18 is fine compared to the rest of the industry. VACC outperforms 76.29% of its industry peers.
There is no outstanding debt for VACC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.18
ROIC/WACCN/A
WACC9.06%
VACC Yearly LT Debt VS Equity VS FCFVACC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 15.26 indicates that VACC has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.26, VACC belongs to the top of the industry, outperforming 88.06% of the companies in the same industry.
VACC has a Quick Ratio of 15.26. This indicates that VACC is financially healthy and has no problem in meeting its short term obligations.
VACC has a better Quick ratio (15.26) than 88.23% of its industry peers.
Industry RankSector Rank
Current Ratio 15.26
Quick Ratio 15.26
VACC Yearly Current Assets VS Current LiabilitesVACC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

VACC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -4723.33%.
VACC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -58.53%.
Measured over the past years, VACC shows a very strong growth in Revenue. The Revenue has been growing by 86.87% on average per year.
EPS 1Y (TTM)-4723.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-251.22%
Revenue 1Y (TTM)-58.53%
Revenue growth 3Y86.87%
Revenue growth 5YN/A
Sales Q2Q%-98.04%

3.2 Future

VACC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -98.17% yearly.
The Revenue is expected to decrease by -60.57% on average over the next years. This is quite bad
EPS Next Y-1733.53%
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
EPS Next 5Y-98.17%
Revenue Next Year-95.74%
Revenue Next 2Y-84.84%
Revenue Next 3Y-75.62%
Revenue Next 5Y-60.57%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VACC Yearly Revenue VS EstimatesVACC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
VACC Yearly EPS VS EstimatesVACC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VACC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VACC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VACC Price Earnings VS Forward Price EarningsVACC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VACC Per share dataVACC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

VACC's earnings are expected to decrease with -153.10% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%

More info and screens

0

5. Dividend

5.1 Amount

VACC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VACCITECH PLC

NASDAQ:VACC (11/6/2023, 8:00:01 PM)

After market: 4.9 -0.1 (-2%)

5

+0.51 (+11.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)N/A N/A
Inst Owners38.61%
Inst Owner Change0%
Ins Owners26.92%
Ins Owner Change0%
Market Cap192.73M
Analysts81.82
Price Target9.5 (90%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.31%
Min EPS beat(2)-11.12%
Max EPS beat(2)6.51%
EPS beat(4)2
Avg EPS beat(4)32.49%
Min EPS beat(4)-30.8%
Max EPS beat(4)165.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-57.42%
Min Revenue beat(2)-69.41%
Max Revenue beat(2)-45.42%
Revenue beat(4)1
Avg Revenue beat(4)-11.6%
Min Revenue beat(4)-69.41%
Max Revenue beat(4)91.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.13%
EPS NY rev (1m)0%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)400%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.36
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.35
BVpS5.63
TBVpS4.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.32%
ROE -25.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 174.45%
Cap/Sales 63.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.26
Quick Ratio 15.26
Altman-Z 3.18
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)156.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)149.12%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4723.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-251.22%
EPS Next Y-1733.53%
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
EPS Next 5Y-98.17%
Revenue 1Y (TTM)-58.53%
Revenue growth 3Y86.87%
Revenue growth 5YN/A
Sales Q2Q%-98.04%
Revenue Next Year-95.74%
Revenue Next 2Y-84.84%
Revenue Next 3Y-75.62%
Revenue Next 5Y-60.57%
EBIT growth 1Y-82.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1689.94%
EBIT Next 3Y-191.11%
EBIT Next 5YN/A
FCF growth 1Y39.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.71%
OCF growth 3YN/A
OCF growth 5YN/A